These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1679916)

  • 1. Additive effect of 1% apraclonidine hydrochloride to nonselective beta-blockers.
    Yaldo MK; Shin DH; Parrow KA; Lee SH; Lee SY
    Ophthalmology; 1991 Jul; 98(7):1075-8. PubMed ID: 1679916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.
    Stewart WC; Ritch R; Shin DH; Lehmann RP; Shrader CE; van Buskirk EM
    Arch Ophthalmol; 1995 Mar; 113(3):287-92. PubMed ID: 7887841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
    Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M
    Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
    Konstas AG; Maltezos A; Mantziris DA; Sine CS; Stewart WC
    Eye (Lond); 1999 Jun; 13 ( Pt 3a)():314-8. PubMed ID: 10624424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study.
    Nagasubramanian S; Hitchings RA; Demailly P; Chuniaud M; Pannarale MR; Pecori-Giraldi J; Stodtmeister R; Parsons DG
    Ophthalmology; 1993 Sep; 100(9):1318-23. PubMed ID: 8371918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy.
    Simsek S; Ertürk H; Demirok A; Cinal A; Yasar T; Karadenizli C
    Eur J Ophthalmol; 1998; 8(3):167-72. PubMed ID: 9793771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of apraclonidine in long-term timolol users.
    Gharagozloo NZ; Brubaker RF
    Ophthalmology; 1991 Oct; 98(10):1543-6. PubMed ID: 1683697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group.
    Robin AL; Ritch R; Shin DH; Smythe B; Mundorf T; Lehmann RP
    Am J Ophthalmol; 1995 Oct; 120(4):423-32. PubMed ID: 7573299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers.
    Yüksel N; Güler C; Caglar Y; Elibol O
    Int Ophthalmol; 1992 Sep; 16(4-5):337-42. PubMed ID: 1358852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effect of apraclonidine on intraocular pressure in glaucoma patients receiving timolol and pilocarpine.
    Yüksel N; Elibol O; Caglar Y; Alçelik T
    Ophthalmologica; 1997; 211(6):354-7. PubMed ID: 9380353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
    Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP
    Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
    Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
    Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of apraclonidine 1% in preventing intraocular pressure rise following macular hole surgery.
    Sciscio A; Casswell AG
    Br J Ophthalmol; 2001 Feb; 85(2):164-8. PubMed ID: 11159479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma.
    Nishimoto JH; Chang FW; Tang IH; Kolin T
    J Am Optom Assoc; 1999 Apr; 70(4):233-9. PubMed ID: 10457699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-daily levobunolol for glaucoma therapy.
    Rakofsky SI; Lazar M; Almog Y; LeBlanc RP; Mann C; Orr A; Lee PF; Friedland BR; Novack GD; Kelley EP
    Can J Ophthalmol; 1989 Feb; 24(1):2-6. PubMed ID: 2653592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apraclonidine hydrochloride: an evaluation of plasma concentrations, and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleate.
    Robin AL; Coleman AL
    Trans Am Ophthalmol Soc; 1990; 88():149-59; discussion 159-62. PubMed ID: 1982747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy.
    Robin AL
    Ophthalmology; 1993 May; 100(5):628-33. PubMed ID: 8098520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD and 0.5% levobunolol hydrochloride BID in patients with ocular hypertension or open-angle glaucoma.
    Halper LK; Johnson-Pratt L; Dobbins T; Hartenbaum D
    J Ocul Pharmacol Ther; 2002 Apr; 18(2):105-13. PubMed ID: 12002664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.